A Survival Analysis Comparing Women with Ovarian Low-grade Serous Carcinoma to Those with High-grade Histology

Overview

Journal Onco Targets Ther

Publisher Dove Medical Press

Specialty Oncology

Date 2014 Oct 25

PMID 25342912

Citations 16

Authors

Ming Chen

Ying Jin

Yalan Bi

Jie Yin

Yongxue Wang

Lingya Pan

Affiliations

Soon will be listed here.

Abstract

Ovarian low-grade serous carcinoma (LGSC) and high-grade serous carcinoma have distinct molecular profiles, clinical behaviors, and treatment responses. The survival advantage for patients with low-grade carcinoma compared with patients with high-grade histology remains controversial. We retrospectively reviewed the medical charts of 381 patients with ovarian serous carcinoma at Peking Union Medical College Hospital from 2007 to 2010. Patients were classified into two groups according to MD Anderson two-tier system: 35 (9.2%) cases with LGSC and 346 with high-grade serous carcinoma. Patients with low-grade serous ovarian cancer had a significantly younger age at diagnosis (46 versus 56 years, P=0.046), and their median progression-free survival (PFS) and overall survival values were 35.0 and 54.0 months, respectively. A multivariate analysis showed that, for serous ovarian cancer, the histological grade was a significant prognostic factor for PFS but not for overall survival (P=0.022 and P=0.0566, respectively). When stratified by the existence of a residual disease, patients with low-grade disease who underwent cytoreductive surgery without macroscopic residual disease (>1 cm) had a significantly improved median PFS time (36.0 months) compared with that of patients with high-grade carcinoma who received optimal cytoreductive surgery (16.0 months, P=0.017). Conversely, patients with low-grade and high-grade carcinoma who were left with macroscopic residue (>1 cm) experienced a similarly shorter median PFS (10.0 and 13.0 months, respectively, P=0.871). The International Federation of Gynecology and Obstetrics stage and residual disease were significant prognostic factors of low-grade carcinoma, while positive ascites was associated with a worse PFS value. Our data showed that LGSC is a different entity from high-grade carcinoma and that LGSC was associated with improved PFS after optimal cytoreductive surgery but not suboptimal operation.

Citing Articles

The impact of varying levels of residual disease following cytoreductive surgery on survival outcomes in patients with ovarian cancer: a meta-analysis.

Chase D, Mahajan A, Scott D, Hawkins N, Kalilani L BMC Womens Health. 2024; 24(1):179.

PMID: 38491366 PMC: 10941390. DOI: 10.1186/s12905-024-02977-5.

The pivotal role of long non-coding RNAs as potential biomarkers and modulators of chemoresistance in ovarian cancer (OC).

Malgundkar S, Tamimi Y Hum Genet. 2024; 143(2):107-124.

PMID: 38276976 DOI: 10.1007/s00439-023-02635-0.

Correlation between progression-free survival and overall survival in patients with ovarian cancer after cytoreductive surgery: a systematic literature review.

Chase D, Mahajan A, Scott D, Hawkins N, Kalilani L Int J Gynecol Cancer. 2023; 33(10):1602-1611.

PMID: 37643825 PMC: 10579502. DOI: 10.1136/ijgc-2023-004487.

Cytoreductive Surgery With or Without HIPEC in the Management of Peritoneal Dissemination from Rare Histological Subtypes of Ovarian Cancer - a Retrospective Study by INDEPSO.

Sinukumar S, Damodaran D, Ray M, Prabhu A, Katdare N, Vikram S Indian J Surg Oncol. 2023; 14(Suppl 1):74-81.

PMID: 37359936 PMC: 10284742. DOI: 10.1007/s13193-022-01640-5.

Exosomes as crucial emerging tools for intercellular communication with therapeutic potential in ovarian cancer.

Malgundkar S, Tamimi Y Future Sci OA. 2023; 9(1):FSO833.

PMID: 37006229 PMC: 10051132. DOI: 10.2144/fsoa-2022-0032.

References

Shih I, Kurman R . Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol. 2004; 164(5):1511-8. PMC: 1615664. DOI: 10.1016/s0002-9440(10)63708-x. View

Diaz-Padilla I, Malpica A, Minig L, Chiva L, Gershenson D, Gonzalez-Martin A . Ovarian low-grade serous carcinoma: a comprehensive update. Gynecol Oncol. 2012; 126(2):279-85. DOI: 10.1016/j.ygyno.2012.04.029. View

Malpica A, Deavers M, Lu K, Bodurka D, Atkinson E, Gershenson D . Grading ovarian serous carcinoma using a two-tier system. Am J Surg Pathol. 2004; 28(4):496-504. DOI: 10.1097/00000478-200404000-00009. View

Schlumbrecht M, Sun C, Wong K, Broaddus R, Gershenson D, Bodurka D . Clinicodemographic factors influencing outcomes in patients with low-grade serous ovarian carcinoma. Cancer. 2011; 117(16):3741-9. PMC: 4254832. DOI: 10.1002/cncr.25929. View

Kobel M, Kalloger S, Huntsman D, Santos J, Swenerton K, Seidman J . Differences in tumor type in low-stage versus high-stage ovarian carcinomas. Int J Gynecol Pathol. 2010; 29(3):203-11. DOI: 10.1097/PGP.0b013e3181c042b6. View

Gershenson D, Sun C, Lu K, Coleman R, Sood A, Malpica A . Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary. Obstet Gynecol. 2006; 108(2):361-8. DOI: 10.1097/01.AOG.0000227787.24587.d1. View

Fader A, Java J, Ueda S, Bristow R, Armstrong D, Bookman M . Survival in women with grade 1 serous ovarian carcinoma. Obstet Gynecol. 2013; 122(2 Pt 1):225-232. PMC: 4870595. DOI: 10.1097/AOG.0b013e31829ce7ec. View

ONeill C, Deavers M, Malpica A, Foster H, McCluggage W . An immunohistochemical comparison between low-grade and high-grade ovarian serous carcinomas: significantly higher expression of p53, MIB1, BCL2, HER-2/neu, and C-KIT in high-grade neoplasms. Am J Surg Pathol. 2005; 29(8):1034-41. View

Crum C, Drapkin R, Miron A, Ince T, Muto M, Kindelberger D . The distal fallopian tube: a new model for pelvic serous carcinogenesis. Curr Opin Obstet Gynecol. 2007; 19(1):3-9. DOI: 10.1097/GCO.0b013e328011a21f. View

10.

May T, Shoni M, Crum C, Xian W, Vathipadiekal V, Birrer M . Low-grade and high-grade serous Mullerian carcinoma: review and analysis of publicly available gene expression profiles. Gynecol Oncol. 2012; 128(3):488-92. DOI: 10.1016/j.ygyno.2012.12.009. View

11.

Gershenson D, Sun C, Bodurka D, Coleman R, Lu K, Sood A . Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant. Gynecol Oncol. 2009; 114(1):48-52. DOI: 10.1016/j.ygyno.2009.03.001. View

12.

Ahmed N, Stenvers K . Getting to know ovarian cancer ascites: opportunities for targeted therapy-based translational research. Front Oncol. 2013; 3:256. PMC: 3782691. DOI: 10.3389/fonc.2013.00256. View

13.

Salani R, Bristow R . Surgical management of epithelial ovarian cancer. Clin Obstet Gynecol. 2012; 55(1):75-95. DOI: 10.1097/GRF.0b013e31824b4629. View

14.

Schmeler K, Sun C, Bodurka D, Deavers M, Malpica A, Coleman R . Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum. Gynecol Oncol. 2007; 108(3):510-4. DOI: 10.1016/j.ygyno.2007.11.013. View

15.

Ali R, Kalloger S, Santos J, Swenerton K, Gilks C . Stage II to IV low-grade serous carcinoma of the ovary is associated with a poor prognosis: a clinicopathologic study of 32 patients from a population-based tumor registry. Int J Gynecol Pathol. 2013; 32(6):529-35. DOI: 10.1097/PGP.0b013e31827630eb. View

16.

Park D, Yeo S, Wilson M, Yerbury J, Kwong J, Welch W . Clusterin interacts with Paclitaxel and confer Paclitaxel resistance in ovarian cancer. Neoplasia. 2008; 10(9):964-72. PMC: 2517641. DOI: 10.1593/neo.08604. View

17.

LaChance J, Shutter J, Atkins K, Stoler M, Rice L, Jazaeri A . Utilization of a uniform grading system for interpreting serous ovarian cancer. Am J Obstet Gynecol. 2008; 199(2):189.e1-6. DOI: 10.1016/j.ajog.2008.04.031. View

18.

Bodurka D, Deavers M, Tian C, Sun C, Malpica A, Coleman R . Reclassification of serous ovarian carcinoma by a 2-tier system: a Gynecologic Oncology Group Study. Cancer. 2011; 118(12):3087-94. PMC: 11809296. DOI: 10.1002/cncr.26618. View

19.

Borley J, Wilhelm-Benartzi C, Brown R, Ghaem-Maghami S . Does tumour biology determine surgical success in the treatment of epithelial ovarian cancer? A systematic literature review. Br J Cancer. 2012; 107(7):1069-74. PMC: 3461167. DOI: 10.1038/bjc.2012.376. View

20.

Romero I, Sun C, Wong K, Bast Jr R, Gershenson D . Low-grade serous carcinoma: new concepts and emerging therapies. Gynecol Oncol. 2013; 130(3):660-6. DOI: 10.1016/j.ygyno.2013.05.021. View